Anixa Biosciences’ (ANIX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a report issued on Wednesday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

A number of other analysts have also issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Anixa Biosciences in a research report on Monday, December 29th. Wall Street Zen raised Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. Finally, Zacks Research lowered shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $9.00.

Anixa Biosciences Trading Up 7.6%

Shares of ANIX opened at $2.96 on Wednesday. The company’s 50-day moving average price is $3.48 and its 200 day moving average price is $3.58. Anixa Biosciences has a 12-month low of $2.33 and a 12-month high of $5.46. The firm has a market cap of $98.80 million, a P/E ratio of -8.46 and a beta of 0.53.

Anixa Biosciences (NASDAQ:ANIX) last announced its earnings results on Monday, January 12th. The company reported ($0.09) earnings per share for the quarter, hitting the consensus estimate of ($0.09). Equities research analysts forecast that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Arnold M. Baskies acquired 10,000 shares of the company’s stock in a transaction on Wednesday, January 28th. The shares were bought at an average cost of $3.04 per share, with a total value of $30,400.00. Following the transaction, the director owned 135,000 shares in the company, valued at approximately $410,400. This trade represents a 8.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 26.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Anixa Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of ANIX. Susquehanna International Group LLP boosted its position in shares of Anixa Biosciences by 378.4% during the 3rd quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock worth $265,000 after acquiring an additional 63,584 shares in the last quarter. Prosperity Wealth Management Inc. boosted its holdings in Anixa Biosciences by 14.5% in the third quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock valued at $138,000 after purchasing an additional 5,300 shares in the last quarter. Citadel Advisors LLC boosted its holdings in Anixa Biosciences by 31.6% in the third quarter. Citadel Advisors LLC now owns 96,010 shares of the company’s stock valued at $317,000 after purchasing an additional 23,072 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Anixa Biosciences by 1.7% in the 3rd quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock valued at $706,000 after buying an additional 3,645 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Anixa Biosciences by 2.1% during the third quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company’s stock worth $4,694,000 after purchasing an additional 29,436 shares during the last quarter. Institutional investors and hedge funds own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.